东北制药集团股份有限公司 章 程 2026 年 3 月 | | 1 | | --- | --- | | 1 | . | | 第一章 总 则 | | --- | | 第二章 经营宗旨和范围 | | 第三章 股 份 | | 第一节 股份发行 | | 第二节 股份增减和回购 . | | 第三节 股份转让 | | 第四章 股东和股东会 . | | 第一节 股东的一般规定 . | | 第二节 控股股东和实际控制人 10 | | 第三节 股东会的一般规定 | | 第四节 股东会的召集 | | 第五节 股东会的提案与通知 15 | | 第六节 股东会的召开 . | | 第七节 股东会的表决和决议 21 | | 第五章 党 委 . | | 第六章 董事会 . | | 第一节 董事 . | | 第二节 董事会 30 | | 第三节 独立董事 ……………………………………………………… 36 | | | | 第一章 总 则 第一条 为规范公司的组织和行为，维护公司、股东和债权 人的合法权益，规范公司的组织和行为，根据《中国共产党章程》 《中华人民共和国公司法》（以下简称《公司法》）《中华人民共 和国证券法》（以下简称《证券法》） ...

北京德恒律师事务所 关于东北制药集团股份有限公司 2026 年第一次临时股东会的 法律意见 北京市西城区金融街 19 号富凯大厦 B 座 12 层 电话：010-52682888 传真：010-52682999 邮编：100033 （一）《公司章程》； 北京德恒律师事务所 关于东北制药集团股份有限公司 2026 年第一次临时股东会的法律意见 北京德恒律师事务所 关于东北制药集团股份有限公司 2026 年第一次临时股东会的 法律意见 德恒 01G20240159 号 致：东北制药集团股份有限公司 东北制药集团股份有限公司（以下简称"公司"）2026 年第一次临时股东 会（以下简称"本次会议"）于 2026 年 3 月 4 日（星期三）召开。北京德恒律 师事务所接受公司委托，指派李哲律师、王冰律师（以下简称"德恒律师"）出 席本次会议。根据《中华人民共和国公司法》(以下简称"《公司法》")、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》 （以下简称"《股东会规则》"）、《东北制药集团股份有限公司章程》（以下 简称"《公司章程》"）的规定，德恒律师就本次会议的召集、召开程序、现场 出席 ...

证券代码：000597 证券简称：东北制药 公告编号：2026-010 东北制药集团股份有限公司 2026 年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1．本次股东会未出现否决议案的情形。 2.现场会议地点：沈阳经济技术开发区昆明湖街 8 号，东北制药集团股份有 限公司。 3.召开方式：采用现场表决与网络投票相结合的方式召开。 4.召集人：公司董事会 2．本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1.本次会议召开的时间： （1）现场会议召开时间：2026 年 3 月 4 日 14:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2026 年 3 月 4 日 9:15 至 9:25，9:30 至 11:30，13:00 至 15:00；通过深圳证券交 易所互联网投票系统进行网络投票的具体时间为 2026 年 3 月 4 日 9:15 至 15:00。 5.主持人：公司董事长周凯先生 6.本次股东会会议召开符合有关法律、行政法规、部门规章、规范性文 ...

Core Viewpoint - Northeast Pharmaceutical is significantly increasing its R&D investment, with R&D expenses reaching 104 million yuan in the first three quarters of 2025, a year-on-year increase of 95%, focusing on innovative drug pipelines such as cell therapy [1] R&D Investment - The company’s R&D expenses for the first three quarters of 2025 amounted to 104 million yuan, reflecting a 95% year-on-year growth [1] - Key investments are directed towards innovative drug pipelines, particularly in cell therapy [1] Clinical Trials and Product Development - The company’s subsidiary, Beijing Dingcheng Peptide Source, has received approval for clinical trials of DCTY0801 injection and has obtained orphan drug designation from the FDA [1] - DCTY1102 injection, a TCR-T drug, is the first targeted KRAS G12D product to enter Phase I clinical trials in China, showcasing the company's technological breakthroughs in biopharmaceuticals [1] Financial Performance - After the mixed-ownership reform, the operational efficiency of Northeast Pharmaceutical has improved, with a projected net profit attributable to shareholders of 410 million yuan for 2024, representing a year-on-year increase of 14.34% [1] - In the first three quarters of 2025, the company's non-recurring net profit increased by 27.54% year-on-year, indicating strong profitability resilience and successful innovation transformation [1] Quality Assurance and Market Trust - The company’s raw material drug manufacturing facility passed audits from seven domestic and international clients in mid-February, covering five core products including Vitamin C, achieving a 100% pass rate [1] - This success further consolidates the company's trust in the international market [1] Stock Performance - Recently, Northeast Pharmaceutical's stock has shown volatility, closing at 5.20 yuan on February 26, 2026, with a daily decline of 0.38% and a cumulative increase of 1.36% over the last three trading days [1] - On February 26, the main capital inflow was 7.87 million yuan, while retail investors showed a net outflow [1] - Technically, the stock price is positioned between a resistance level of 5.5 yuan and a support level of 5.06 yuan, with a weak MACD indicator, indicating a need to monitor breakout situations in the short term [1]

七年春节坚守，智能制造助力医药保供加速 除夕夜，在辽宁方大集团东北制药细河原料药厂区202分厂外包装操作室内，伴随着机器轰鸣声，一箱 箱盐酸小檗碱有序完成包装。 "设备专人负责、实时巡检、记录留痕，每一道工序都不能马虎。"林艳一边紧盯设备参数，一边向贝壳 财经记者介绍，"我们优化了包装节奏，减少工序等待，1月份已经超额完成产量计划，就是要全力以赴 冲刺一季度'开门红'，保障市场供应不脱节。" 进入东北制药28年，今年已是林艳第七次在岗位上度过春节。 春节前的排班，从来不是一件简单的事。但在林艳眼里，这份"难题"却总能在默契中化解。 "外地的员工，家远的，优先让他们先回，别耽误了团圆。"这是每年排班时不成文的规矩。车间里，离 家近的、本地的同事会主动往前站，等外地同事返岗后，大家再轮换着休息。 春节期间，东北制药202分厂盐酸小檗碱后部工段的灯火依旧通明。工段长林艳又一次出现在春节值班 表里，这已经是她连续第七年在岗位上度过春节假期。 作为医药生产线上的一名"老兵"，林艳深知自己手中生产的原料药产品，都可能是下游药企和患者节日 里的急需。而在医药企业的生产厂区和药房门店内，像林艳这样坚守岗位的员工随处可见：十多 ...

Core Viewpoint - The article highlights the ongoing production activities across various industries in China during the Spring Festival, emphasizing the commitment of companies to maintain supply and meet market demands despite the holiday season [1][3][4]. Group 1: Production Continuity - Over 260 companies in Ningbo and more than 280 industrial enterprises in Luoyang continued production during the Spring Festival, with an increase of approximately 30 companies compared to 2025 [1]. - In Tianjin, around 90 key industrial enterprises maintained continuous production, with an expected overall resumption rate of 86.3% by February 24 [1]. - Sichuan Zhou Hei Ya Food Co., Ltd. reported a daily production of over 50,000 "modified atmosphere packaging" products to ensure supply to stores in multiple regions [1]. Group 2: Market Opportunities - Zhejiang Hengcheng Hard Alloy Co., Ltd. experienced a significant production value increase of 230% year-on-year in January, with over 100 employees working during the holiday to meet tight delivery schedules [3]. - Nanjing Huaxin Fiber Optic Co., Ltd. reported a full operation of 38 fiber optic production lines during the Spring Festival due to high demand, with orders extending into the second half of the year [4]. Group 3: Safety Measures - Guangxi Sun Paper Industry Co., Ltd. implemented strict safety measures during the holiday, including regular inspections and approvals for hazardous operations, to ensure safe production [6]. - The State Council's Work Safety Committee emphasized the importance of safety production during the holiday, focusing on risk prevention in various industries [6]. Group 4: Support and Coordination - The Gansu Lanzhou New Area Project Construction Center coordinated with various departments to address companies' needs, ensuring uninterrupted supply and support during the holiday [7]. - Local governments established 24-hour service hotlines and conducted special visits to ensure continuous production and address any operational challenges faced by enterprises [7].

Core Viewpoint - The report highlights the growth in the chemical raw materials and products manufacturing industry in China, indicating a positive trend in the number of enterprises and overall market potential from 2026 to 2032 [1] Industry Summary - As of January to December 2025, the number of enterprises in the chemical raw materials and products manufacturing industry reached 27,102, an increase of 815 compared to the previous year, representing a year-on-year growth of 3.1% [1] - This sector accounts for 5.15% of the total industrial enterprises in China, reflecting its significance within the broader industrial landscape [1] - The report is based on data from the National Bureau of Statistics and compiled by Zhiyan Consulting, a leading industry consulting firm in China [1] Company Summary - The report mentions several listed companies in the chemical sector, including Hainan Haiyao (000566), Northeast Pharmaceutical (000597), and others, indicating a diverse range of players in the market [1] - Zhiyan Consulting provides comprehensive industry research reports, business plans, feasibility studies, and customized services, emphasizing its role in supporting investment decisions in the chemical industry [1]

Core Viewpoint - Northeast Pharmaceutical Group Co., Ltd. has announced plans to engage in financial derivatives trading to manage foreign exchange and interest rate risks arising from its foreign currency settlements in response to market fluctuations [1] Group 1: Financial Derivatives Trading - The primary objective of this trading initiative is hedging, aimed at locking in costs and avoiding risks rather than engaging in speculation or arbitrage [1] - The maximum trading amount is set at 300 million RMB, which can be rolled over within its validity period [1] - The trading instruments will mainly include forward foreign exchange settlements, currency swaps, options, interest rate swaps, and currency swaps, with trading periods generally not exceeding one year [1] Group 2: Financial Stability and Risk Management - The company emphasizes that all trading funds will come from its own capital and will collaborate with legally qualified domestic and foreign large commercial banks [1] - This initiative is viewed as a significant risk control measure to enhance financial stability and mitigate the potential adverse impacts of exchange rate and interest rate fluctuations on operational performance [1] - The company has established corresponding internal operational processes and risk control measures to prevent market, liquidity, and operational risks [1]

东北制药集团股份有限公司 金融衍生业务管理制度 第一章 总 则 第一条 为规范东北制药集团股份有限公司（以下简称 "公司"）外汇衍生品交易业务及相关信息披露工作，加强 对外汇衍生品交易业务的管理，防范投资风险，健全和完善 公司外汇衍生品交易业务管理机制，确保公司资产安全，根 据《中华人民共和国公司法》《中华人民共和国证券法》《深 圳证券交易所股票上市规则》《深圳证券交易所上市公司自 律监管指引第 1 号——主板上市公司规范运作》等相关法律、 法规、规范性文件的有关规定，结合《公司章程》及公司实 际业务情况，特制定本制度。 第二条 本制度所称外汇衍生品交易是指公司为满足正 常生产经营需要，在金融机构办理的规避和防范汇率风险的 外汇衍生品交易业务，品种具体包括：远期、期货、掉期（互 换）和期权等业务及以上业务的组合。 第三条 本制度适用于公司及控股子公司的外汇衍生品 交易业务，控股子公司开展外汇衍生品交易业务视同公司外 汇衍生品交易业务，适用本制度，但未经公司同意，公司下 属控股子公司不得操作该业务。 第二章 外汇衍生品交易业务操作原则 第四条 公司进行外汇衍生品交易业务遵循合法、审慎、 1 安全、有效的原则，所 ...

东北制药集团股份有限公司 章 程 （修订稿） 2026 年 2 月 | | 1 | | --- | --- | | 1 | . | | 第一章 总 则 | | --- | | 第二章 经营宗旨和范围 | | 第三章 股 份 | | 第一节 股份发行 | | 第二节 股份增减和回购 . | | 第三节 股份转让 | | 第四章 股东和股东会 . | | 第一节 股东的一般规定 . | | 第二节 控股股东和实际控制人 10 | | 第三节 股东会的一般规定 | | 第四节 股东会的召集 | | 第五节 股东会的提案与通知 15 | | 第六节 股东会的召开 . | | 第七节 股东会的表决和决议 21 | | 第五章 党 委 . | | 第六章 董事会 . | | 第一节 董事 . | | 第二节 董事会 30 | | 第三节 独立董事 ……………………………………………………… 36 | | | | 第一章 总 则 第一条 为规范公司的组织和行为，维护公司、股东和债权 人的合法权益，规范公司的组织和行为，根据《中国共产党章程》 《中华人民共和国公司法》（以下简称《公司法》）《中华人民共 和国证券法》（以下简称 ...